BACKGROUND: Patients with end-stage liver disease are known to suffer from a significantly high risk of mortality, but accurate prediction of the course of disease is challenging. OBJECTIVE: The study aim was to evaluate the independent prognostic and clinical importance of serum levels of ferritin and transferrin for 90-day survival of patients with liver disease. METHODS: Patients with end-stage liver disease treated during a 2-year period were enrolled retrospectively in a single-centre study. Unmatched and propensity score matching (PSM) analyses were applied. RESULTS: The study cohort comprised 286 patients with end-stage liver disease, of which 22.9% died during the observational period. High serum ferritin levels and low serum transferrin levels were associated significantly with increased 90-day mortality in the unmatched (p < 0.001) and PSM study population (p = 0.017). Serum levels of ferritin and transferrin had high prognostic capability to predict 90-day survival similar to the Model for End-stage Liver Disease. Patients with serum ferritin values >1030.5 µg/l had a 50% risk of dying within 11 days after measurement, which translated up to a 90-day mortality of 83%. CONCLUSION: Serum levels of ferritin and transferrin have independent and excellent capabilities to determine prognosis in patients with end-stage liver disease. Ferritin measurements can reliably identify those with high mortality in daily practice.
BACKGROUND:Patients with end-stage liver disease are known to suffer from a significantly high risk of mortality, but accurate prediction of the course of disease is challenging. OBJECTIVE: The study aim was to evaluate the independent prognostic and clinical importance of serum levels of ferritin and transferrin for 90-day survival of patients with liver disease. METHODS:Patients with end-stage liver disease treated during a 2-year period were enrolled retrospectively in a single-centre study. Unmatched and propensity score matching (PSM) analyses were applied. RESULTS: The study cohort comprised 286 patients with end-stage liver disease, of which 22.9% died during the observational period. High serum ferritin levels and low serum transferrin levels were associated significantly with increased 90-day mortality in the unmatched (p < 0.001) and PSM study population (p = 0.017). Serum levels of ferritin and transferrin had high prognostic capability to predict 90-day survival similar to the Model for End-stage Liver Disease. Patients with serum ferritin values >1030.5 µg/l had a 50% risk of dying within 11 days after measurement, which translated up to a 90-day mortality of 83%. CONCLUSION: Serum levels of ferritin and transferrin have independent and excellent capabilities to determine prognosis in patients with end-stage liver disease. Ferritin measurements can reliably identify those with high mortality in daily practice.
Authors: Marta Ledesma; Yamilee Hurtado-Roca; Montserrat Leon; Pilar Giraldo; Miguel Pocovi; Fernando Civeira; Eliseo Guallar; Jose Maria Ordovas; Jose Antonio Casasnovas; Martin Laclaustra Journal: J Clin Endocrinol Metab Date: 2015-02-19 Impact factor: 5.958
Authors: Ralph G Depalma; Virginia W Hayes; Bruce K Chow; Galina Shamayeva; Patricia E May; Leo R Zacharski Journal: J Vasc Surg Date: 2010-03-20 Impact factor: 4.268
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Mohammad A B Al-Freah; Stephen Kriese; Matthew R Foxton; Alberto Quaglia; Adrian Bomford; Nigel D Heaton; John G O'Grady; Kosh Agarwal; Julia A Wendon; Michael A Heneghan Journal: Transpl Int Date: 2013-11 Impact factor: 3.782
Authors: Nurdan Guldiken; Josepmaria Argemi; Berivan Gurbuz; Stephen R Atkinson; Martin Oliverius; Petr Fila; Karim Hamesch; Tony Bruns; Joaquín Cabezas; Juan J Lozano; Jelena Mann; Sheng Cao; Philippe Mathurin; Vijay H Shah; Christian Trautwein; Mark R Thursz; Ramon Bataller; Pavel Strnad Journal: BMC Med Date: 2021-02-17 Impact factor: 8.775